Abstract
In leukaemia allogeneic bone marrow transplantation is a method by which high-dose, often curative therapy can be given without regard to marrow toxicity. Applying the same principle to paediatric solid tumours should allow selection of the most active agents for use in combinations, at doses limited only by extramedullary toxicity. The availability of HLA- and DR-matched allografts is very limited, however, restricting this type of marrow transplant to less than one in five children with malignancy. Other options are to use either autologous grafts or mismatched allografts, and at present, autologous bone marrow transplantation (ABMT) is the alternative of choice. ABMT is used either to shorten the period of aplasia after non-ablative high-dose chemotherapy such as melphalan [8] or as a rescue after massive myeloablative chemotherapy, often with total-body irradiation (TBI).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
August CS, Serota FT, Koch PA, Burkey E, Schlesinger H, Elkins WL, Evans AE, D’Angio GJ (1984) Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol 2:609–616
Biron P, Philip T, Maraninchi D, Pico JL, Cahn JY, Fumoleau P, Le Mevel A, Gastaut JL, Carcassonne JM, Kamioner D, Hervé P, Brunat-Mentigny M, Hayat M (1985) Massive chemotherapy and ABMT in progressive disease of non-seminomatous testicular cancer. In: Dicke K, Spitzer G, Zander AR (eds) Autologous bone marrow transplantation. University of Texas, Houston, pp 203–210
Cornbleet M, Corringham R, Prentice H, Boesen E, Mc Elwain TJ (1981) Treatment of Ewing sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat Rep 63:241–244
D’Angio GJ, August C, Elkins W, Evans AE, Seeger R, Lenarsky C, Feig S, Wells J, Ramsay N, Kim T, Woods W, Krivit W, Strandjord S, Coccio P, Novak L (1985) Metastatic neuroblastoma managed by supralethal therapy and bone marrow reconstitution (BMRc). Results of a four-institution children’s cancer study group pilot study. In: Evans AE, D’Angio GJ, Seeger RC (eds) Advances in neuroblastoma research. Liss, New York, pp 557–563
Graham-Pole J, Lazarus HM, Herzig RH, Worthington D, Riley C (1984) High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing sarcoma. Am J Pediatr Hematol Oncol 6:17–26
Hartmann O, Kalifa C, Beaujean F, Bayle C, Benhamou E, Lemerle J (1985) Treatment of advanced neuroblastoma with two consecutive high-dose chemotherapy regimens and ABMT. In: Evans AE, D’Angio GJ, Seeger RC (eds) Advances in neuroblastoma research. Liss, New York, pp 565–568
Kemshead JT, Goldman A, Fritschy J, Malpas JS, Pritchard J (1983) The use of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders. Lancet I:12–15
Kingston JE, Malpas JS, Stiller CA, Pritchard J, Mc Elwain TJ (1984) Autologous bone marrow transplantation contributes to haemopoietic recovery in children with solid tumours treated with high-dose melphalan. Br J Haematol 58:589–595
Mc Elwain TJ, Hedley DW, Gordon MY, Jarman M, Millar JL, Pritchard J (1979) High-dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol 7:[Suppl 5]360–371
Miser J (1986) High-dose therapy and ABMT in pédiatrie solid tumor. In: de Bernardi B (ed) Novel therapeutic approaches in pediatrie oncology. Martinus Nijhoff, Boston (in press)
Munoz LL, Wharam MD, Kaizer H, Leventhal BG, Ruymann F (1983) Magna-field irradiation and autologous marrow rescue in the treatment of pediatrie solid tumors. Int J Radiat Oncol Biol Phys 9:1951–1954
Philip T (1984) Status of the role of ABMT in solid tumors in Europe. Proc of European Bone Marrow Transplant Group, Granada
Philip T, Biron P, Philip I, Favrot M, Bernard JL, Zucker JM, Lutz B, Plouvier E, Rebattu P, Carton M, Chauvot P, Dutou L, Souillet G, Philippe N, Boridigoni P, Lacroze M, Clapisson G, Olive D, Trealaven J, Kemshead JT, Brunat-Mentigny M (1985) Autologous bone marrow transplantation for very bad prognosis neuroblastoma. In: Evans AE, D’Angio GJ, Seeger RC (eds) Advances in neuroblastoma research. Liss, New York, pp 568–586
Phillips GL, Fay JW, Herzig G, et al. (1983) Intensive 1,3-bis (2 chloroethyl)-1-nitrosourea (BCNU) and cryopreserved autologous marrow transplantation for refractory cancer. A phase I–II study. Cancer 52:1792–1802
Pritchard J, Mc Elwain TJ, Graham-Pole J (1982) High-dose melphalan with autologous bone marrow rescue for treatment of advanced neuroblastoma. Br J Cancer 48:86–92
Pritchard J, Germona S, Jones D, De Kraker J, Love S (1986) Is high-dose melphalan of value in treatment of advanced neuroblastoma? Proc ASCO, vol 5, A 805
Prats J, Toledo J, Payarols J, Gallego S, Macio J (1985) High-dose melphalan therapy for the treatment of children with refractory Wilms tumor. Proc SIOP, p 289
Saarinan UM, Coccia PF, Gerson SL, Pelley R, Cheung NKV (1985) Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement. Method for purging autologous bone marrow. Cancer Res 45:5969–5975
Shafford EA, Rogers DW, Pritchard J (1984) Advanced neuroblastoma: improved response rate using malignant regimen (OPEC) including sequential cis-platinum and VM26. J Clin Oncol 2:742–747
Treleaven JG, Gibson FM, Ugelstad J, Rembaum A, Philip T, Caine GD, Kemshead JT (1984) Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet I:70–73
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Pinkerton, R., Philip, T. (1987). Autologous Bone Marrow Transplantation in Paediatric Solid Tumours. In: Neth, R., Gallo, R.C., Greaves, M.F., Kabisch, H. (eds) Modern Trends in Human Leukemia VII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 31. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72624-8_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-72624-8_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-17754-8
Online ISBN: 978-3-642-72624-8
eBook Packages: Springer Book Archive